PhD Scientific Days 2022

Translational Medicine II. (Poster discussion will take place in the Aula during the Coffee Break)

Non-steroidal anti-inflammatory drugs (NSAID) enhance the mEHT effect on TNBC (4T1,4T07) and melanoma(B16F10) tumor models

Előadó neve

Dr. Giunashvili, Nino

Előadó munkahelye

Basic and Translational Medicine

Előadó telefonszáma

705523056

Előadó e-mail címe

nino.giunashvili.3@iliauni.edu.ge

Az előadás címe

Non-steroidal anti-inflammatory drugs (NSAID) enhance the mEHT effect on TNBC (4T1,4T07) and melanoma(B16F10) tumor models

Szerző(k) neve és munkahelye

Nino Giunashvili-MD, PhD student,Institute of Translational Medicine, Semmelweis University, Budapest, Hungary
Jeremiah Thomas-MD,PhDInstitute of Translational Medicine, Semmelweis University, Budapest, Hungary
Lea Danics-Institute of Translational Medicine, Semmelweis University, Budapest, Hungary
Csaba András Schvarcz-Institute of Translational Medicine, Semmelweis University, Budapest, Hungary
Pedro Viana-Institute of Translational Medicine, Semmelweis University, Budapest, Hungary
Kenan Aless-Institute of Translational Medicine, Semmelweis University, Budapest, Hungary
Mahak Zahra-Institute of Translational Medicine, Semmelweis University, Budapest, Hungary
Zoltán Benyó-Institute of Translational Medicine, Semmelweis University, Budapest, Hungary
Péter Hamar - Institute of Translational Medicine, Semmelweis University, Budapest, Hungary

Bemutatás módja

Szóbeli

Szekció

Translational Medicine II. (Poster discussion will take place in the Aula during the Coffee Break)

Language of the presentation

English

Preferred session

Theoretical and Translational Medicine

Összefoglaló szövege

Previous experiments demonstrated that 3 times Modulated Electro Hyperthermia Treatments (mEHT) of 4T1 Triple Negative Breast Cancer (TNBC) mouse model caused acute phase reaction (APR), optimization of the systemic innate immune response and inhibition of tumor growth. Besides, mEHT has elevated Cyclooxygenase2(COX2) and proinflammatory cytokines - IL1 beta and IL6 synthesis. Conversely, mEHT did not stimulate adaptive immune response and secondary immunogenic cell death in our TNBC (4T1, 4T07) models significantly. Descriptive effect of mEHT could be considered as a part of the inflammation, which might have multifaceted roles in tumorigenesis, including immunosurveillance or tumor promoting effects by supporting tumor favorable microenvironment (TME). We hypothesized, that anti-inflammatory therapy could enhance the effect of mEHT. Our group has already studied Acetylsalicylic acid (ASA) and mEHT synergistic effects on melanoma B16F10 cancer model in vivo. In our current research, we combined mEHT with selective (SC236) and non-selective (ASA) COX2 inhibitors on the 4T1 TNBC model, that demonstrated significant diminution of tumor growth and bigger tumor destruction ratio (TDR) compared to mEHT mono therapy. Tumor favorable microenvironment inhibition can be one of the probable explanations of the abovementioned synergism, which molecular mechanism is going to be investigated further.

Funding: EFOP-3.6.3-VEKOP-16-2017-00009

University and Doctoral School

Semmelweis University, Doctoral School of Theoretical and Translational Medicine

Supervisor

Peter Hamar

Publication of my abstract

I give consent to the publication of my abstract on the website of the congress.

Kind

Szabad

Status

elfogadva

Accepted presentation method

szóbeli

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

6857

Start

12:15

End

12:30

Authors (legacy)

Nino Giunashvili-MD, PhD student,Institute of Translational Medicine, Semmelweis University, Budapest, Hungary
Jeremiah Thomas-MD,PhDInstitute of Translational Medicine, Semmelweis University, Budapest, Hungary
Lea Danics-Institute of Translational Medicine, Semmelweis University, Budapest, Hungary
Csaba András Schvarcz-Institute of Translational Medicine, Semmelweis University, Budapest, Hungary
Pedro Viana-Institute of Translational Medicine, Semmelweis University, Budapest, Hungary
Kenan Aless-Institute of Translational Medicine, Semmelweis University, Budapest, Hungary
Mahak Zahra-Institute of Translational Medicine, Semmelweis University, Budapest, Hungary
Zoltán Benyó-Institute of Translational Medicine, Semmelweis University, Budapest, Hungary
Péter Hamar - Institute of Translational Medicine, Semmelweis University, Budapest, Hungary